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Résumé en
anglais
Our review of cohort studies and clinical trials evaluating antihypertensive drugs in
the prevention of cognition decline and all dementia in patients with hypertension
indicates that two antihypertensive drug classes have greater protective effects,
independent of blood pressure decrease: dihydropyridine calcium-channel blockers as
shown in the Syst-Eur trial and angiotensin-AT1 receptor blockers as found in the
MOSES and ONTARGET trials. By contrast, diuretics and angiotensin-converting
enzyme-inhibitors (ACEIs) prevent dementia only in patients with a stroke history,
provided they are combined, and prevent stroke recurrence. A Japanese cohort study
and a small trial in patients already suffering from Alzheimer’s disease (AD) suggest,
however, that the BBB-penetrating ACEI may slow down cognitive decline. Only
cohort studies support the hypothesis that diuretics, (especially potassium-sparing
diuretics), may decrease the risk of AD. β-blockers worsen cognition decline, or are
neutral, according to whether or not they cross the BBB. Centrally-acting
sympatholytic agent have a negative impact on cognition as BBB-penetrating β-
blockers, probably by blunting the adrenergic pathways. The AD protective effect of
DHP appears related to the blockade of neuronal calcium channels. The ambiguous
effect of ACEI on cognitive decline and dementia prevention may be explained by the
fact that brain ACE is not specific for angiotensin-I. Brain ACE also catabolizes
cognition-enhancing brain peptides, amyloid peptides and converts toxic Aβ42 into less
toxic Aβ40. Therefore, ACEIs may have short-term cognition-enhancing properties and
may increase in the long term Aβ42 brain burden and cognitive decline. The clinical
relevance of this scenario, mainly observed in animals, cannot be excluded in man,
since the ACE gene has been associated with AD via the human whole genome
analysis. To support the hypothesized deleterious effect of ACEI on human AD,
confirmation that the ACE gene polymorphism DD is associated with protection
against AD is necessary, since this polymorphism increases ACE activity.
Independently of their preventive impact on β-amyloid degenerative
neuropathological process by overexpressing insulin degrading enzyme which
catabolyses amyloid, the angiotensin AT1-receptor-blockers may have greater
cognition protective effects than ACEI (observed in the ONTARGET trial), as they
share with ACEI cognition-enhancing effects directly linked with a common AT1-
blunting effect. In addition, they increase angiotensin II and IV formation and
therefore stimulate non-opposed AT2 and AT4 receptors, whose activation in
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